Saturday, January 23, 2010
Can CF Teens and Parents Find Common Ground??


Friday, January 22, 2010
My First Ever Chinese Train Station Experience
Thursday, January 21, 2010
Thankful for Fun!


Wednesday, January 20, 2010
Put Your Health at the Top of the List!!



Tuesday, January 19, 2010
The Top Ten Foods That Make Me (CF) Bloated
Monday, January 18, 2010
We Sure Do Have a Great Life Don't We?



Sunday, January 17, 2010
Cystic Fibrosis History and Timeline
1936 - Fanconi refers to the previously nameless condition as "cystic fibrosis with bronchiectasis."
1938 - Andersen of Columbia University develops the first comprehensive description of cystic fibrosis symptoms. CF also named Mucovicidosis.
1949 - Lowe establishes that cystic fibrosis is a recessive genetic disorder.
1953 - After observing excessive dehydration of cystic fibrosis patients during a New York City heat wave, di Sant' Agnese of Columbia University formally reports to the American Pediatric Society that CF patients secrete excessive amounts of salt in their sweat. This observation leads to development of the sweat test as a diagnostic standard for cystic fibrosis.
1955 - A group of volunteers, including parents of children with CF and physicians meet to form the CF Foundation, headquartered in Philadelphia; among the group is Milton Graub, M.D., a pediatrician and father of two children with CF, who later becomes the CF Foundation’s third president and who remains active in the CF Foundation today; life expectancy for people with CF is 5 years old.
1961 - The CF Foundation establishes the first CF care centers; CF Foundation hosts first conference of CF care center directors.
1962 - Additional CF centers established, bringing total to 30. Predicted median survival increases to about 10 years.
1965 - CF Foundation begins clinical fellowship program; George Frankel, a CF Foundation founder, establishes Guidance, Action and Projection conferences, a fellowship program to bring basic scientists into the field of CF research.
1966 - CF Foundation establishes Patient Data Registry, which tracks the histories of patients treated at CF care centers.
1968 - CF Foundation hosts first National/International Medical Conference.
1972 - First national seminar on needs of young adults with CF held by CF Foundation.
1978 - Headquarters moves to Washington, D.C. to be close to the federal government and the National Institutes of Health (NIH); first nationwide fund-raising event held, called Bowl for Breath, nearly doubling the fund-raising dollars for CF. The number of Cystic Fibrosis Foundation-accredited care centers now total 125.
Early 1980's - Researchers associate organ damage caused by CF with a malfunction of the epithelial tissue.
1980 - Robert J. Beall, Ph.D. comes to the CF Foundation as medical director from NIH.
1981 - Satellite CF care centers for adults were established for the first time; life expectancy reaches 20 years.
1982 - The CF Foundation creates the Research Development Program (RDP) to encourage leading academic and scientific institutions to establish centers of excellence in CF research; Doris Tulcin, Chairman Emeritus of CF Foundation, launches a capital campaign—the first of its kind by a voluntary health agency—to raise $15 million to support the creation of the RDP; Robert K. Dresing becomes volunteer president of the CF Foundation, later becoming the first president and CEO.
1983 - Scientists show that cells lining the lungs fail to properly move chloride into the airways; the Orphan Drug Act is signed into law and provides companies with financial incentives for developing drugs for rare diseases like CF; Frank Deford, sportswriter and novelist, writes the book, Alex: The Life of a Child about his daughter who died from CF at the age of 8; Deford becomes Chairman of the CF Foundation’s Board of Trustees.
1984 - American Airlines, Outstanding Corporate Partner of the CF Foundation, hosts the first Celebrity Ski event to benefit the CF Foundation.
1985 - Life expectancy reaches 25 years.
1986 - The movie, “Alex: The Life of a Child” appears on ABC putting CF in the national spotlight; CF Foundation tops $20 million in fund-raising.
1988 - CF Foundation establishes Cystic Fibrosis Services—a specialty pharmacy—to provide availability, access and assistance with the complex insurance issues faced in obtaining CF medications.
1989 - Francis Collins, M.D., Ph.D., John Riordian, M.D., and Lap-Chee Tsui, Ph.D. discover the CF gene with support from the CF Foundation’s RDP; CF Foundation hosts first GREAT STRIDES walk-a-thon, now a $20 million+ annual fund-raising event. A Team led by Tsui and Riordan of the Hospital for Sick Children in Toronto discover the gene responsible for CF and name its protein product cystic fibrosis transmembrane conductance regulator (CFTR). The gene is mapped to chromosome 7q.
1990 - CF researchers achieve test tube “proof of concept” for gene therapy.
1993 - FDA approves Pulmozyme, the first biotech drug designed for CF, which breaks down thick CF mucus following studies in CF care center network; first gene therapy tested in person with CF—shows gene therapy corrects CF cells in nasal passages; CF Foundation and NIH establish nine gene therapy centers for CF studies; Beall becomes president and CEO of the CF Foundation; The Boomer Esiason Foundation redirects its mission to support the CF Foundation when Esiason's son, Gunnar, is diagnosed with CF.
1996 - The Seattle Breath of Life Gala, which has raised more than $24 million since its inception in 1984, becomes the CF Foundation’s first “million dollar event,” raising $1,002,500 in one night; CF Foundation forms public policy alliance, a grassroots group of volunteers who inform policy decision makers.
1997 - FDA approves TOBI, an inhaled antibiotic, after CF Foundation-supported studies showed safety and efficacy; CF Foundation establishes the Therapeutics Development Program (TDP) with seven centers in the Therapeutics Development Network (TDN); CF Foundation forms Adult Task Force to address specific issues facing adults with CF.
1999 - Bill and Melinda Gates Foundation gives the CF Foundation a $20 million grant for drug discovery; Cam C. Cooper is named Chairman of the CF Foundation’s Board of Trustees.
2000 - CF Foundation-supported researchers complete map of Pseudomonas aeruginosa genome; CF Foundation establishes CF National Bioinformatics Center to help spur discovery of new treatments; CF Foundation awards contract to Aurora Biosciences for up to $46.9 million for CF drug discovery (the largest grant of its kind by a nonprofit organization); CF Foundation establishes Cystic Fibrosis Foundation Therapeutics, Inc. to govern CF Foundation’s drug discovery and evaluation efforts.
2001 - Tom Marsico, CEO of Marsico Capital Management, LLC, commits $25 million over several years in support of the TDP; CF Foundation makes first multi-million award for drug development with Altus® Pharmaceuticals, Inc. to develop TheraClec TM Total, a potentially more efficient pancreatic enzyme.
2002 - Results of CF Foundation-supported clinical trial on azithromycin show that the drug is effective in improving lung function in people with CF; the TDN expands to 18 centers.
2003 - Targeted Genetics, Inc., with CF Foundation support, begins a Phase II CF gene therapy trial that represents the largest and most advanced gene therapy trial for CF to date; CF Foundation tops $150 million in fund-raising; CF Foundation launches Volunteer Leadership Initiative, to bring 2,003 new volunteers to the CF Foundation in 2003.
2004 - Results from Inspire Pharmaceutical’s CF Foundation-supported clinical trial of INS37217 to restore ion transport demonstrate both safety and improvement in lung function in people with CF; pipeline of CF therapeutics in development includes nearly two-dozen potential therapies; CF Foundation recommends nationwide newborn screening for CF at North American CF Conference, which now includes nearly 3,000 attendees; life expectancy increases to the mid-30s.
2005 - Predicted median age of survival increases to nearly 37 years.
2006 - Cystic Fibrosis Foundation Therapeutics-supported studies in Australia and UNC show that hypertonic saline helps clear CF mucus and becomes a therapeutic option.
2006 - The first compound for CF, discovered through high-throughput screening at Vertex Pharmaceuticals, begins clinical trials.
2006 - Inspire Pharmaceuticals begins Phase 3 clinical trials of its innovative denufosol drug to hydrate and clear CF mucus.
2007 - VX-770, a potentiator candidate developed by Vertex Pharmaceuticals, entered Phase 2 testing. This drug may restore the function of the CFTR protein. Vertex also is working to develop corrector candidates, which aim to improve the function of the CFTR.
Saturday, January 16, 2010
Breastfeeding and Cystic Fibrosis
Kacie: I had always known that I was going to exclusively breastfeed my children so the decision was made before Lucy was even born. When Lucy arrived, and because she had the blockages, I was not able to nurse her for 2 whole weeks. Imagine my frustration and heart ache to not be able to nurse my child when she cried for me! She never ingested a single thing until 2 weeks old, waiting for her insides to heal up. She was given fluids and nutrients through an IV while I pumped, pumped and pumped, and saved every last drop of milk I could get. I made the NICU nurses write in huge, red lettering, "MOTHER'S BREAST MILK ONLY!" in her file so she would never be given formula. The very first thing that went into Lucy's repaired intestines was exactly 5ml of my milk. She was not to be given more than 5-10ml at a time to insure that the surgery went well. After 2 days of "testing" her new tummy out, we were finally, at last, able to nurse. I will never forget the first time either! She latched on like she had done it before. We were off and running. The doctors were very pleased that I was so adamant about breastfeeding. The recommendations about switching to formula came later. Lucy was not gaining as much as she should have been gaining according to the AAP weight charts. When she dipped below 50th percentile, it was mentioned that we may have to supplement with formula for added calories. I told them that giving her formula would never happen in a million years! I went home that day and started nursing her around the clock like normal, but I added in feedings as well, even when she really didn't even have hunger cues. I became a human pacifier because I refused to put her on formula. Extra nursing worked. She gained enough weight to get above the 50th percentile so Lucy's nutritionist never mentioned formula to me again.
Wendy: How has breastfeeding proved to be a great help in relation to Lucy's diagnosis and her illness in general?
Kacie: I make jokes that my boob has been my best friend and still is! Lucy has been in and out of doctors offices her whole life. Her life is very chaotic and stressful because of CF. More stress than a child should have to go through: blood tests, needles, throat cultures, wearing a vest that shakes her chest and taking up to 9 different medications a day. By nursing Lucy on demand for the last 2 years, we have created a safe place for her to go where she knows everything will be okay. Nursing is her neutral place, a safe place, the quiet place among the storm. I am more in tune with her and her physical and emotional needs because of our nursing relationship. Nursing her for this long has helped her immune system. She is sick less often and when she does get sick it is very short-lived. If I ever get a cold or illness, she has never gotten it from me. She is receiving the antibodies from me that are needed in fighting the infection. I really cannot think of one negative thing to say about breastfeeding Lucy.


Friday, January 15, 2010
First Day Out of the Hospital...


Thursday, January 14, 2010
Haiti, Rain and Community


Wednesday, January 13, 2010
Started a New Running Plan!
Mon | Tues | Wed | Thurs | Friday | Sat. or Sun. | |
Week 1 | Walk 6 min., run 1 min. Repeat 3 times (total 21 min.) | Repeat Monday's workout | Repeat Monday's workout | |||
Week 2 | Walk 5 min., run 2 min. Repeat 4 times (total 28 min.) | Repeat Monday's workout | Repeat Monday's workout | |||
Week 3 | Walk 3 min., run 4 min. Repeat 4 times (total 28 min.) | Repeat Monday's workout | Repeat Monday's workout | Repeat Monday's workout | ||
Week 4 | Walk 2 min., run 5 min. Repeat 4 times (total 28 min.) | Repeat Monday's workout | Repeat Monday's workout | Repeat Monday's workout | ||
Week 5 | Walk 2 min., run 8 min. Repeat 3 times (total 30 min.) | Repeat Monday's workout | Repeat Monday's workout | Repeat Monday's workout | ||
Week 6 | Walk 2 min., run 9 min. Repeat 3 times (total 33 min.) | Repeat Monday's workout | Repeat Monday's workout | Repeat Monday's workout | ||
Week 7 | Walk 1 min., run 11 min. Repeat 3 times (total 36 min.) | Repeat Monday's workout | Repeat Monday's workout | Repeat Monday's workout | ||
Week 8 | Walk 5 min., run 20 min., walk 5 min. (total 30 min.) | Walk 5 min., run 23 min., walk 5 min. (total 33 min.) | Walk 5 min., run 26 min., walk 5 min. (total 36 min.) | Walk 5 min., run 30 min., walk 5 min. (total 40 min.) |
Once you're up to running 30 minutes straight, try to stick with this four times a week.
Tuesday, January 12, 2010
My Top Ten Most Frequented Websites



Sunday, January 10, 2010
Who Wants to Dream With Us???



Welcome to Joshland!!


Saturday, January 9, 2010
The Cells of CF
I thought this article did a good job explaining what is going on in the cells of a CFer, cause remember, it's not a lung disease. Cystic Fibrosis is a CELL disease.
Inhibition of Proteostasis Restores Ion Channels in CF Cells
Tuesday January 5, 2010Our cells are full of enzymes that mediate activities like growth, metabolism, replication,transcription and cell signalling. They are all unique in their structure, and have evolved over time to perform the specific functions for which they are made. Some enzymes are hydrophillic(water-loving, or water soluble) and remain in the cytoplasm of the cell, while others arehydrophobic, thus more lipophillic. The lipophillic enzymes are generally found embedded in cell membranes and tend to have roles such as mediating the transport of small molecules and ions across the membrane. Cystic fibrosis transmembrane conductance regulator (CFTR) is one such membrane protein.
In order to study its structure and function, it is necessary to first purify a protein. Like all hydrophobic transmembrane proteins, study of CFTR is hindered because it is difficult to purify and study in a stable form. However, it has been determined that mutations in the gene encoding CFTR result in an improper protein structure, that folds incorrectly, is recognized as defective by cellular machinery, and is destroyed.
Without CFTR, chloride ion transport in the lungs is hindered, resulting in a mucus buildup characteristic of the disease. Efforts to treat CF by altering the gene or protein structures in patients have not been terribly effective, but last month a study was published that showedrestoration of ion transport could be achieved by controlling the actions of a class of enzymes responsible for proteostasis (destruction of proteins) called histone deacetylases (HDACs). A compound called suberoylanilide hydroxamic acid (SAHA), already approved by the FDA for treatment of lymphoma, was able to restore up to 28% of channel activity in isolated cell cultures from CF patients. The authors, Hutt et al., postulated that by preventing destruction of imperfect proteins, those polymorphisms that are not completely disfunctional can restore some ion exchange capacity in cell membranes.
Full article at http://biotech.about.com/b/2010/01/05/inhibition-of-proteostasis-restores-ion-channels-in-cf-cells.htm
Make sense??

